Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA Congress
Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA Congress Natick, Mass . – May 28, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that data for its lead compound KPT-330
View HTML
Toggle Summary Karyopharm Therapeutics Raises $48.2 Million in Series B Financing
-Will fund development of lead compound KPT-330 through pivotal studies in two oncology indications -
View HTML
Toggle Summary Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitors of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual Meeting
Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitors of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual Meeting Natick, Mass . – May 15, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that clinical data for its lead
View HTML
Toggle Summary Karyopharm Therapeutics to Present Data on Selective Inhibitors of Nuclear Export (SINE) to treat Influenza and HIV at International Congress on Antiviral Research (ICAR)
Karyopharm Therapeutics to Present Data on Selective Inhibitors of Nuclear Export (SINE) to treat Influenza and HIV at International Congress on Antiviral Research (ICAR) Natick, Mass. May 9, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces
View HTML
Toggle Summary Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association of Cancer Research (AACR) Meeting
Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association of Cancer Research (AACR) Meeting Natick, Mass. March 26, 2013 Karyopharm Therapeutics Inc., a leader in the new field of
View HTML
Toggle Summary Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & Development
Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & Development Natick, Mass. February 5th 2013 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces that Ken Weg and Barry
View HTML
Toggle Summary Karyopharm Therapeutics Initiates Treatment of Patients with Acute Myeloid Leukemia (AML) in Phase 1 Trial with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)
Karyopharm Therapeutics Initiates Treatment of Patients with Acute Myeloid Leukemia (AML) in Phase 1 Trial with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE) Natick, Mass. – January 17, 2013 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport
View HTML
Toggle Summary Karyopharm Therapeutics Initiates a Phase IIb Efficacy Study with its Novel, Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Non-Hodgkin Lymphomas (NHL)
Karyopharm Therapeutics Initiates a Phase IIb Efficacy Study with its Novel, Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Non-Hodgkin Lymphomas (NHL) Natick, Mass. December 4, 2012 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators,
View HTML
Toggle Summary Karyopharm Therapeutics Announces Eight Presentations on Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at the American Society of Hematology (ASH) Meeting
Five oral and three poster presentations on Clinical Stage SINE CRM1 Antagonists
View HTML
Toggle Summary Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE) Karyopharm Therapeutics Announces Oral Presentation at the
View HTML